Feature | November 22, 2011

Canadian Task Force Recommends Against Breast Cancer Screening for Women Under 50

Canadian Task Force Recommends Against Breast Cancer Screening for Women Under 50

November 21, 2011 — The Canadian Task Force on Preventive Health Care has released an updated guideline for breast cancer screening in average-risk women aged 40 to 74, published in the Canadian Medical Association Journal. The new guideline, which weighs the potential harms of false positives and unnecessary biopsies against the potential benefits of breast cancer screening in average risk women, updates prior guidelines by the Task Force from 1994 and 2001 and recommends against routine screening for women under age 50.

The Task Force was established by the Public Health Agency of Canada to develop clinical practice guidelines that support primary care providers in delivering preventive healthcare. It is an independent body of 15 primary care and prevention experts who recognise and support the need for evidence-informed preventive activities in primary care in Canada. Its mandate is to develop and disseminate clinical practice guidelines for primary and preventive care, based on systematic analysis of scientific evidence.

The new recommendations are presented for the use of mammography, magnetic resonance imaging (MRI), breast self-exam and clinical breast exam to screen for breast cancer. They apply only to women at average risk of breast cancer aged 40 to 74 years. They do not apply to women at higher risk due to personal history of breast cancer, history of breast cancer in a first-degree relative, known BRCA1/BRCA2 mutation or prior chest wall radiation. No recommendations are made for women aged 75 and older, given the lack of data.

The specific recommendations and the Task Force’s comments and bases for its recommendations are as follows:

Mammography: For women aged 40 – 49 we recommend not routinely screening with mammography. (Weak recommendation; moderate-quality evidence) The likelihood of breast cancer is lower and the likelihood of false positive results on mammography is greater in younger women. This recommendation places a relatively low value on a very small absolute decrease in breast cancer mortality and reflects concerns with unnecessary diagnostic testing and overdiagnosis (diagnosis of breast cancer that will not affect length or quality of life). Women who place a higher value on a small reduction in breast cancer mortality and are less concerned about the potential harms may choose screening. About 470 women aged 40-49 die of breast cancer in Canada each year.

For women aged 50-69 years we recommend routinely screening with mammography every 2 to 3 years. (Weak recommendation; moderate-quality evidence) Women who do not place a high value on a small reduction in breast cancer mortality and are concerned about false positive results of mammography and overdiagnosis may decline screening. About 1,900 women aged 50-69 die of breast cancer in Canada each year.

For women aged 70 - 74 we recommend routinely screening with mammography every 2 to 3 years. (Weak recommendation; low quality evidence) Women who do not place a high value on a small reduction in breast cancer mortality and are concerned about false positive results of mammography and overdiagnosis may decline screening. About 480 women aged 70-74 die of breast cancer in Canada each year.

Magnetic Resonance Imaging: We recommend not routinely screening with magnetic resonance imaging (Weak recommendation; no evidence)

Clinical Breast Exam: We recommend not routinely performing clinical breast exam alone or in conjunction with mammography to screen for breast cancer. (Weak recommendation; low-quality evidence)

Breast Self Exam: We recommend not advising women to routinely practice breast self exam (Weak recommendation; moderate-quality evidence).

For more information: www.canadiantaskforce.ca

Related Content

Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Hologic Acquires Digital Specimen Radiography Company Faxitron Bioptics

VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.

News | Breast Imaging | July 31, 2018
Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital...
Konica Minolta Hosting Lunch and Learn at 23rd Annual Mammography Meeting in Santa Fe
News | Breast Imaging | July 31, 2018
Konica Minolta Healthcare Americas Inc. will sponsor a lunch and learn featuring its Exa Mammo platform during the 23rd...
FDA Approves New Tomosynthesis Quality Control Tests for ACR Digital Mammography QC Manual
News | Mammography | July 30, 2018
The U.S. Food and Drug Administration (FDA) recently approved the American College of Radiology’s (ACR’s) amendment to...
The Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal. The FDA granted approval of the Sentimag System to Endomagnetics Inc.

The  Endomagnetics' Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal.

Technology | Women's Health | July 24, 2018
July 24, 2018 — The U.S.
Overlay Init